Welcome to our dedicated page for Stryker SEC filings (Ticker: SYK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Stryker Corporation (NYSE: SYK) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8-K, annual and quarterly reports, and other materials that describe Stryker’s financial condition, governance and material events as a global medical technologies company focused on MedSurg, Neurotechnology and Orthopaedics.
Current reports (Form 8-K) play a central role in Stryker’s disclosure practices. For example, the company has filed 8-Ks to furnish press releases announcing second and third quarter 2025 operating results, detailing net sales, segment performance and earnings metrics. Another Form 8-K dated December 4, 2025 reports leadership changes, including the appointment of a President and Chief Operating Officer and a new Group President, Orthopaedics, and summarizes related compensation arrangements.
Through its SEC filings, Stryker also identifies its registered securities and capital structure. Filings list the company’s common stock, traded on the New York Stock Exchange under the symbol SYK, along with multiple series of senior unsecured notes with different maturities that are also listed on the NYSE. These disclosures help investors understand the instruments available for investing in Stryker and the company’s obligations under its notes.
On Stock Titan, Stryker’s filings are updated in step with new submissions to the SEC’s EDGAR system. AI-powered tools summarize key points from lengthy documents, helping readers quickly identify items such as results of operations, leadership changes, segment commentary and descriptions of registered securities. Users can review Stryker’s historical and recent filings to track how the company reports on its MedSurg, Neurotechnology and Orthopaedics businesses, financial performance and governance over time.
Stryker Corporation (SYK): Form 144 notice of proposed sale. A security holder filed to sell up to 2,026 shares of SYK common stock. The filing lists an aggregate market value of $740,482, an approximate sale date of 11/14/2025, and execution on the NYSE through UBS Financial Services Inc.
The shares were acquired on 11/14/2025 via an options exercise, with payment by wire on the same date. Shares outstanding were 382,164,865; this is a baseline figure, not the amount being sold.
Stryker Corp (SYK) director Ronda E. Stryker reported open‑market sales of common stock on 11/05–11/06/2025. The trades were executed in multiple tranches at weighted‑average prices between $349.455 and $359.80 per share.
Following these transactions, 2,702,108 shares were beneficially owned indirectly by a Revocable Trust. Additional holdings shown include 13,578,805 shares indirectly by the L. Lee Stryker Trust, 37,600 shares indirectly by the 1988 William D. Johnston Trust, and 1,213 shares held directly.
SYK filed a Form 144 notice for a proposed secondary sale of 520,000 shares of common stock, with an aggregate market value $184,600,000. The filing lists Apex Clearing as broker and the approximate date of sale 11/05/2025 on the NYSE.
The notice also reports 382,307,000 shares outstanding as context. Acquisition history shows 10,000,000 common shares acquired on 05/01/1974 via an estate division from the Estate of L. Lee Stryker. Recent activity includes the Ronda E Stryker Revocable Trust selling 200,000 shares on 08/06/2025 for $75,283,700 in gross proceeds.
This is a resale by an existing holder; cash proceeds flow to the selling holder rather than the company.
Stryker Corporation reported an insider transaction by its VP, Chief Financial Officer on a Form 4. On 11/01/2025, the officer recorded a transaction in Common Stock with Transaction Code F, involving 404 shares at $356.24.
Following the transaction, the officer beneficially owned 6,859 shares directly and 287 shares indirectly through a 401(k). A footnote states this total includes 204 shares acquired under the Employee Stock Purchase Plan as of September 30, 2025.
Stryker (SYK) filed its Q3 2025 10‑Q reporting double‑digit top‑line growth. Net sales rose to $6,057 million from $5,494 million, and diluted EPS was $2.22 versus $2.16. For the nine months, revenue reached $17,945 million with diluted EPS of $6.20.
Growth was broad-based: MedSurg and Neurotechnology sales increased 14.4% to $3,803 million, while Orthopaedics rose 3.9% to $2,254 million. Vascular and Neuro Cranial stood out, reflecting the February acquisition of Inari Medical, which added minimally invasive venous thromboembolism products. Operating income was $1,135 million, and net earnings were $859 million.
Cash flow from operations improved to $2,901 million for the nine months, while investing cash flow of $(4,561) million reflected $4,810 million for the Inari acquisition. The company issued $3,000 million of senior notes and repaid $650 million, ending with total debt of $16,595 million and cash of $3,256 million. Stryker completed the sale of its Spinal Implants business. Shares outstanding were 382,423,648 as of September 30, 2025.
Stryker Corporation filed a current report to furnish a press release announcing its third quarter 2025 operating results. The company states that the press release, dated October 30, 2025, is attached as Exhibit 99.1.
The report clarifies that the information in the press release and this filing is being furnished rather than filed, which affects how it is treated under securities laws and future SEC filings. The document is signed on behalf of Stryker by its Vice President and Chief Financial Officer.
Insider transaction summary: Stryker Corporation director and Group President Viju Menon reported a sale of 500 shares of Stryker common stock on 08/25/2025 at a reported price of $390.61 per share. After the sale, Mr. Menon beneficially owns 12,511 shares directly and 197 shares indirectly through a 401(k) plan. The Form 4 was signed by an attorney-in-fact on 08/27/2025.
Stryker Corporation (SYK) Form 144 notice discloses a proposed sale of 500 shares of Stryker common stock to be executed through UBS Financial Services on 08/25/2025 on the NYSE. The securities were acquired on 03/21/2025 via PSU Vesting from Stryker Corp and paid by wire on the same acquisition date. The filing reports an aggregate market value of 195,305 for the 500 shares and shows 382,164,865 shares outstanding; no securities were reported sold in the past three months. Certain filer identification fields in the provided content (CIK and contact details) are not present in the text.
Robert S. Fletcher, VP and Chief Legal Officer of Stryker Corporation (SYK), reported an insider sale on 08/20/2025. The Form 4 shows a disposition of 1,785 shares of Stryker common stock at a reported price of $393.07 per share. After the reported sale, Mr. Fletcher beneficially owned 10,457 shares directly and 162 shares indirectly through a 401(k) account. The filing was signed on 08/21/2025 by an attorney-in-fact for Mr. Fletcher. The form indicates this was an individual filing by one reporting person and does not list any derivative transactions.
Stryker Corporation (SYK) filing a Form 144 notifies the proposed sale of 1,785 common shares through UBS Financial Services on 08/20/2025 on the NYSE. The filing reports an aggregate market value of 701,620 and shows total shares outstanding of 382,164,865. The shares were acquired via RSU vesting in three tranches: 443 shares on 08/01/2023, 908 shares on 03/21/2024, and 434 shares on 08/01/2024; payments associated with those acquisitions were by wire. The filer indicates no securities sold in the past three months and affirms they possess no undisclosed material information about the issuer.